Sensei Biotherapeutics appoints William Ringo as Chair of Board

Sensei Biotherapeutics, Inc.

William Ringo appointed Chair of the Board effective March 8, 2022; also joins compensation and nominating committees.
Mr. Ringo brings 40+ years of pharma/biotech experience including Pfizer SVP, Eli Lilly executive roles, and CEO of Abgenix.
Received an option to purchase 29,100 shares and RSU awards totaling 18,933 shares; annual retainers of $79,000.
Press release announcing appointment issued March 9, 2022.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

William Ringo

Chair of the Board

SNSE · Sensei Biotherapeutics, Inc.

Effective: 2022-03-08
Filed: March 9, 2022, 6:59 PM ET

Effective March 8, 2022, the board of directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) appointed William Ringo to serve as Chair of the Board of the Company and as a member of the Company’s compensation committee and nominating and corporate governance committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William Ringo was appointed as Chair of the Board at Sensei Biotherapeutics, Inc..

Action: appointed
Role: Chair of the Board

Exact text from the filing

Effective March 8, 2022, the board of directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) appointed William Ringo to serve as Chair of the Board of the Company and as a member of the Company’s compensation committee and nominating and corporate governance committee.

View on SEC.gov

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-070592

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.